Aurigene Press Release: First Patient Dosed with AUR101 in Phase II Study
Posted by
www.biotecnika.org
Aurigene Announces First Patient Dosed with AUR101 in Phase II Study
in Patients with Moderate to Severe Psoriasis Aurigene, a
development-stage biotechnology company, today announced dose
administration for the first patient in INDUS-2, a Phase II
double-blind placebo-controlled three-arm study of AUR101 in patients
with moderate to severe psoriasis. AUR101 is an oral small molecule
[…]
The post Aurigene Press Release: First Patient Dosed with AUR101 in
Phase II Study appeared first on Rasayanika .
https://www.rasayanika.com/2020/02/19/aurigene-first-patient-dosed-with-aur101-press-release-announcment/
News
Subscribe to:
Post Comments (Atom)
Post a Comment